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Background: Pharmacological cognitive enhancement, using chemicals to change cellular
processes in the brain in order to enhance one’s cognitive capacities, is an often discussed
phenomenon. The prevalence among Dutch university students is unknown.
Methods: The study set out to achieve the following goals: (1) give an overview of different
methods in order to assess the prevalence of use of prescription, illicit and lifestyle
drugs for cognitive enhancement (2) investigate whether polydrug use and stress have
a relationship with cognitive enhancement substance use (3) assessing opinions about
cognitive enhancement prescription drug use. A nationwide survey was conducted among
1572 student respondents of all government supported Dutch universities.
Results: The most detailed level of analysis—use of specific substances without a
prescription and with the intention of cognitive enhancement—shows that prescription
drugs, illicit drugs and lifestyle drugs are respectively used by 1.7, 1.3, and 45.6% of the
sample. The use of prescription drugs and illicit drugs is low compared to other countries.
We have found evidence of polydrug use in relation to cognitive enhancement. A relation
between stress and the use of lifestyle drugs for cognitive enhancement was observed.
We report the findings of several operationalizations of cognitive enhancement drug use
to enable comparison with a wider variety of previous and upcoming research.
Conclusions: Results of this first study among university students in the Netherlands
revealed a low prevalence of cognitive enhancement drug use compared to other
countries. Multiple explanations, such as a difference in awareness of pharmacological
cognitive enhancement among students, accessibility of drugs in the student population
and inclusion criteria of enhancement substances are discussed. We urge enhancement
researchers to take the different operationalizations and their effects on the prevalence
numbers into account.
Keywords: cognitive enhancement, neuroenhancement, smart drugs, prescription stimulants, non-medical use,
illicit drugs, lifestyle drugs, self-report
INTRODUCTION
Recently the topic of cognitive enhancement has received much
attention, both in popular media (e.g., Schwarz, 2012; Sharrett,
2012; Shiner, 2013; Monks, 2014) and academic literature (e.g.,
a special issue on cognitive enhancers by Neuropharmacology
Lynch et al., 2013). Cognitive enhancement can be accomplished
in a variety of ways. Some methods use advanced technology
to modulate brain activity, e.g., deep brain stimulation, whilst
other methods are based on chemicals that are aimed at changing
the cellular processes in the brain, also named pharmacological
cognitive enhancement. Pharmacological cognitive enhancement
refers to boosting cognitive capacities by using substances, with
the aim to enhance one’s performance above baseline levels
(e.g., Bostrom and Sandberg, 2009). Most substances regularly
referred to in the discussion about pharmacological cognitive
enhancement were originally developed to treat neuropsychi-
atric disorders that are often accompanied by cognitive deficits.
A drug widely reported to be used with the purpose of pharma-
cological cognitive enhancement is methylphenidate (e.g., Ritalin,
Concerta), which was developed as a treatment for attention
deficit hyperactivity disorder (ADHD). Other drugs often used to
boost cognitive capacities include modafinil and amphetamines
(Ragan et al., 2013). However, recently also other substances,
such as caffeine and nicotine as well as several illicit drugs,
are included in the discussion of the cognitive enhancement
literature (e.g., Franke et al., 2011b, 2012; Wolff et al., 2014).
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The expectations of the effect prescription drugs for cognitive
enhancement exert in healthy individuals often exceed their real
effect (Repantis et al., 2010). Whether effective or not, the preva-
lence studies have shown that some people do experiment with
drugs to boost their (cognitive) performance (Smith and Farah,
2011).
Herman-Stahl et al. (2007) suggested that the use of prescrip-
tion drugs to improve one’s cognitive performance is especially
common among individuals in cognitively demanding environ-
ments, such as schools and universities. The authors showed that
college students are more likely to use prescription stimulants for
nonmedical purposes than young adults who are not enrolled in
college, although no intentions of use (e.g., recreational, or to
enhance performance) were examined in this study. In addition,
most of the prevalence studies conducted so far have focused on
the university student population. Smith and Farah (2011) give
an overview of 28 epidemiological studies on the prevalence of
nonmedical prescription drug use that were conducted among
secondary and post-secondary students in the US and Canada
before July 2010. The prevalence numbers of lifetime nonmed-
ical stimulant use among university students ranged from 5.3%
in an online study reaching over 2000 respondents (DuPont et al.,
2008) to 55% in a study among 307 fraternity members (DeSantis
et al., 2009). Smith and Farah (2011) conclude that it is hard to
draw quantitative conclusions from the list of studies, as they dif-
fer inmany ways. For example, there are marked differences in the
way the prevalence numbers are calculated, where some studies
include all nonmedical use, others only include nonmedical use
with the intention to enhance ones cognitive performance. This
means that in the latter condition users with solely recreational or
experimental intentions are excluded from the prevalence num-
bers that are presented. Moreover, some studies focus solely on
the intention, meaning that also individuals with a prescription
are counted as a cognitive enhancement drug user when they
report to use these drugs for nonmedical reasons, while others
exclude all users with a prescription regardless of their intention
of use. Smith and Farah (2011) also describe a large variation
between studies in sampling method and demographic charac-
teristics, ranging from studies examining a single department at a
single institution to nationwide epidemiological surveys on non-
medical drug use. These differences have a major influence on
the outcome of the studies because of several factors that can
vary between institutions or regions. In a national cross-section
study of over 10,000 students enrolled at 4-year colleges McCabe
et al. (2005) demonstrated, that the nonmedical use of prescrip-
tion stimulants was higher in the North-Eastern region of the
US, compared to other regions, and higher for institutions with
more competitive admission criteria compared to less competi-
tive admission criteria. Finally, a difference can be found in the
way that cognitive enhancement drugs are addressed in the ques-
tionnaire, for example by either questioning general drug use for
the purpose of enhancement or questioning the use of specific
types of stimulants (e.g., Ritalin) and/or active ingredient (e.g.,
methylphenidate) for this purpose. The latter limits the num-
ber of stimulants and/or active ingredients that are taken into
account in the survey, but leads to more specific questions for the
respondent.
Recently more and more studies have been conducted on the
university student population in (mostly Western) Europe. The
aforementioned variety in definitions and demographic charac-
teristics cause difficulty in comparing the prevalence numbers of
these studies as well. For example, Holloway and Bennett (2012)
are sometimesmentioned in the discussion on cognitive enhance-
ment drugs, while they focus on general nonmedical use and only
briefly mention the intention of cognitive enhancement. From
the sample of 1614 students 33% reported to use prescription
drugs nonmedical, but only three students reported the reason
“to study.” Castaldi et al. (2012) on the other hand, focus solely
on the intention, and thus include two students who have a pre-
scription in their prevalence number of 16% of students who use
cognitive enhancement drugs in a sample of 77 Italian medical
students. Also Pustovrh and Mali (2014) did a (pilot) study in
only a single institution, in Slovenia, resulting in a prevalence of
11 out of 211 students (5.21%) who had ever used prescription
drugs for cognitive enhancement.
In contrast to the aforementioned studies, the focus of stud-
ies seems to shift from prevalence of substance use for cognitive
enhancement toward broader topics, such as the motives behind
the use, differences between users and non-users, or theoretically
grounded accounts of why certain students choose to use drugs
for cognitive enhancement while others do not (Eickenhorst et al.,
2012; Sattler and Wiegel, 2013; Wolff and Brand, 2013; Wolff
et al., 2013, 2014; Ott and Biller-Andorno, 2014). However, preva-
lence numbers are usually presented as well and will be reviewed
here even though they are not always the primary aim of study.
Larger studies in Germany and Switzerland demonstrate differ-
ences in targeting specific substances or a more general group of
pharmacological cognitive enhancers. Sattler and Wiegel (2013),
for example, examined prior use by asking whether respondents
had ever used a prescription medicine without medical necessity
to enhance cognitive efficiency, resulting in a lifetime preva-
lence of 4.56%. Ott and Biller-Andorno (2014) examined the
particular use of Ritalin, Adderall or Modasomil among 1765 stu-
dents at one Swiss university, and found a prevalence of 6.2%
of 1765 students who use prescription drugs without a pre-
scription to increase concentration or alertness, of which 4.7%
more specifically reported study purposes. However, they claim
the questionnaire is not designed to be representative for their
population. Maier et al. (2013) examined the use of 17 specific
substances with the intention to enhance cognitive performance,
categorized as prescription drugs (e.g., methylphenidate), drugs
of abuse (e.g., alcohol) and other substances (e.g., caffeine). They
found a prevalence of 7.6% for nonmedical prescription drug use
for cognitive enhancement and 7.8% for drugs of abuse for cog-
nitive enhancement among their sample of 6275 students from
three Swiss universities. This points to a more widespread phe-
nomenon among several surveys in Germany, to not only include
prescription drugs as potential enhancers, but also illicit drugs
and/ormore commonly available substances (also: lifestyle drugs)
such as coffee and energy drinks. Most studies clearly separate
them, such as Wolff et al. (2014), who demonstrated the use
of lifestyle, prescription and illicit drugs for cognitive enhance-
ment among approximately 1000 students all over Germany, and
found a lifetime prevalence of respectively, 83.2, 5.8, and 3.5%.
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Franke et al. (2011a,b) surveyed the use of coffee, caffeinated
drinks, caffeine tablets, prescription drugs, and illicit drugs for
cognitive enhancement among high school and undergraduate
students and found a prevalence of respectively, 53.2, 39, 10.5,
1.3, and 2.6%. However, other researchers in Germany diverge
from this distinction between lifestyle, prescription and illicit
drugs, and group them in one general class of cognitive enhancers.
Dietz et al. (2013), for instance, report a 12-month prevalence
of use of cognitive-enhancing drugs of 20%. In this number the
authors include the use of prescription drugs, illicit drugs and
caffeine tablets. Eickenhorst et al. (2012) grouped prescription
drug use and illicit drug use to improve cognitive performance or
mood, and found a prevalence of 7% among 1324 students and
graduates.
The current study does not aim to solve the problems that
arise due to different definitions, sampling methods or ques-
tions, nor do we aim to provide a theoretical framework for
pharmacological cognitive enhancement drug use. We aim to
contribute to the discussion by examining different study meth-
ods in the same sample. This creates the possibility to directly
compare the influence of certain questions and inclusion crite-
ria on the resulting prevalence number. Furthermore, the present
study sets out to assess the prevalence of pharmacological cogni-
tive enhancement by means of a web-based survey administered
to university students in the Netherlands, a sample that to our
knowledge has not been examined before. There are only a few
studies investigating the use of cognitive enhancers in the Dutch
population. Ganpat et al. (2009) surveyed the illicit use of pre-
scription drugs with the intention to improve performance in
sport and study among adolescents between 14 and 17 years
old and found an overall prevalence rate of 1.7%. A second
study assessed the quantity of psychopharmacological enhance-
ment among Dutch psychiatrists and other physicians working in
psychiatry (Timmer and Glas, 2012). The results demonstrated a
lifetime prevalence of 11%. This latter number is comparable to
recent results of a survey among German surgeons (Franke et al.,
2013).
In an attempt to reach a representative sample our survey
has been advertised online and offline among students of all
14 government supported universities in the Netherlands. The
survey examines the prevalence of general nonmedical use of
prescription drugs, and the use of particular prescription drugs
(methylphenidate, modafinil, beta blockers, and rivastigmine)
with the specific purpose of cognitive enhancement with and
without a prescription. Furthermore, we will assess the use of
prescription drugs for cognitive enhancement with a question
not targeted at particular drugs, but at the general group of
prescription drugs. Furthermore, we will describe the use of
lifestyle and illicit drugs with the purpose of cognitive enhance-
ment. It is impossible to make a comparison of all defini-
tions and study methods in previous studies, but in this way
many differences of prior studies are addressed, which makes
it possible to directly compare prevalence numbers by different
methods within this study and to studies with similar methods
abroad.
In addition of giving an overview of different prevalence num-
bers of the use of substances for cognitive enhancement in the
student population in the Netherlands, we also examine two top-
ics that have been found to relate to pharmacological cognitive
enhancement, being polydrug use and the relationship between
using cognitive enhancement substances and stress. Polydrug use
considers the finding that there is a positive relationship between
the use of prescription drugs for cognitive enhancement and the
use of other substances in general (Barret et al., 2005; McCabe
et al., 2005; Eickenhorst et al., 2012; Mazanov et al., 2013).
Furthermore, it regards a positive relationship between the use
of prescription drugs for cognitive enhancement, the use of illicit
drugs for cognitive enhancement and the use of lifestyle drugs
for cognitive enhancement, meaning that if somebody uses one
of these for cognitive enhancement, there is a higher chance of
using substances from the other groups with the purpose of cog-
nitive enhancement as well (Maier et al., 2013; Wolff and Brand,
2013; Ott and Biller-Andorno, 2014). We hypothesize that uni-
versity students in the Netherlands will also display polydrug use,
meaning that (1) users of prescription drugs for the purpose of
cognitive enhancement are more likely to use other substances
than non-users and (2) there is a correlation between the use of
prescription, illicit and lifestyle drugs for cognitive enhancement.
Second, Maier et al. (2013) demonstrated that prescription
and illicit drug use for cognitive enhancement is related to per-
ceived pressure to perform. Wolff et al. (2014) found a similar
relation for the use of prescription and lifestyle drug use for cog-
nitive enhancement and self-reported strain. Wolff and Brand
(2013) demonstrated that overwhelming demands in school
could predict the use of prescription drugs and lifestyle drugs for
cognitive enhancement. With a longitudinal design Sattler and
Wiegel (2013) demonstrated that increased cognitive test anx-
iety increased the prevalence of nonmedical prescription drug
use for cognitive enhancement over time. We hypothesize that
a similar relation between the use of cognitive enhancement
substances and stress will be prevalent among students in the
Netherlands; and thus that students who use substances for the
purpose of cognitive enhancement will report more stress than
students who do not use substances for the purpose of cognitive
enhancement.
Finally, several surveys have examined attitudes toward the
use of prescription drugs for cognitive enhancement. In general,
the public displays similar concerns as described in the academic
literature on the topic, concerning topics such as the safety of
using prescription drugs by healthy people, the possibility of
being coerced in using a drug for cognitive enhancement and the
fairness of using drugs to enhance ones cognitive performance
(Schelle et al., 2014). To add to this discussion we assessed opin-
ions in the current sample toward several statements regarding
the safety and policy surrounding the use of prescription drugs
for cognitive enhancement.
To sum up, the survey aimed at (1) giving an overview of
different methods to assess the prevalence of use of substances
for cognitive enhancement and apply these methods to a new
sample of university students in the Netherlands (2) investi-
gating whether findings of polydrug use and the relationship
between cognitive enhancement substance use and stress can also
be applied to this population and (3) assessing opinions about the
use of prescription drugs for cognitive enhancement.
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METHODS
RESPONDENTS
In the current study, 1572 respondents of a total population of
approximately 245,000 students registered at Dutch universities,
replied to a nationwide poster spread, social media advertise-
ments and a letter to student organizations. Prior to analysis 69
respondents were excluded [exclusion criteria were not being a
student at a Dutch university, technical difficulties with the online
questionnaire and an affirmative answer on a control question
(see below)], resulting in a final sample of 1503 respondents
with a mean age of 21.8 years (± sd 2.8 years; 70% women).
The sample included students of all 14 government supported
Dutch universities, although the relative distribution of respon-
dents was not equal for different universities. Respondents were
stimulated to complete the questionnaire by raffling one tablet
PC, 30 shopping vouchers (C15,-) and 20 cinema vouchers
(C7, 50).
PROCEDURE
The questionnaire was an anonymous online survey in Dutch,
which could only be accessed after signing a digital informed
consent form. This form was followed by the questionnaire as
described in a next section. After submission of the question-
naire a new non-related website opened where the respondent
was offered the opportunity to enter in the lottery for the tablet
PC and vouchers. Data were stored in an offline database for later
analysis. Care was taken not to store IP addresses from the respon-
dents in the dataset. Contact information needed for distribution
of the prizes was stored in a separate data file. The procedure and
questionnaire are approved by the Ethics Committee Faculty of
Social Sciences (ECSS) of the Radboud University, Nijmegen, the
Netherlands.
QUESTIONNAIRE
The first section of our questionnaire assessed demographics
and background characteristics. Furthermore, we assessed study
behavior (e.g., time spent studying) and study outcome to be able
to further characterize the cognitive enhancement substance user.
After that, we translated and adapted the “Perceived Stress Scale”
(Cohen et al., 1983) to a version assessing “Perceived Study Stress”
by inserting the word “study” in front of the word “stress” each
time this was mentioned in the original scale. The remainder of
the survey focused on the use of and the opinion about several
substances, the main outcome measures of this study.
The length of the survey depended on the amount of sub-
stances used, because respondents were routed toward more
specific questions about substances. All questions had a forced
response format, meaning that respondents could not skip the
question. For most respondents the survey was about 80 ques-
tions long. On average, respondents took approximately 18min
to complete the survey.
MAIN OUTCOME MEASURES
Type of substances
The main outcome measures concern the use of prescription
drugs, illicit drugs (stimulants, soft drugs and hard drugs)
and lifestyle drugs (alcohol, nicotine, and caffeine). We asked
respondents to indicate their use of prescription drugs in two
different ways, namely with questions about four prescription
drugs in particular (methylphenidate, modafinil, beta blockers,
and rivastigmine) and questions about the use of prescription
drugs in general.
The use of specific prescription drugs was part of a single
question in which we asked respondents to indicate whether
they had used one or more of the following substances since
the start of their university studies, followed by examples as
shown in the following overview: alcohol (e.g., in beer, wine,
liquor), nicotine (e.g., in cigarettes, roll-ups), caffeine (e.g., in
coffee, energy drinks), pharmacy products (such as painkillers,
nutritional supplements), soft drugs (such as marihuana), smart
shop products (such as memory boosters, herb pills), stimulants
(such as amphetamine, cocaine), hard drugs (such as lysergic acid
diethylamide (LSD), heroine), methylphenidate (e.g., in Ritalin),
modafinil (e.g., in Provigil), beta blockers (e.g., in Propanolol)
and rivastigmine (e.g., in Exelon). We added a non-existent
drug to the list of possible substances respondents could indi-
cate to have used. This drug was named “Hoxazine (e.g., in
Hypersotaline)” and was placed there to detect untrustworthy
results. Respondents who admitted to have used this non-existent
drug were excluded from further analysis.
Because we only included four often discussed prescription
drugs that could potentially be used for cognitive enhancement
we also asked a question regarding general prescription drug use.
Respondents were asked to indicate whether they had ever used
a prescription drug without having a prescription themselves. If
they confirmed this question they were routed toward a question
about their reasons for using prescription drugs.
Use of substances
If respondents indicated to have been in contact with a substance
they were routed toward questions about the specific substance(s)
to indicate amount, times and reasons of usage. In the case of
prescription drugs they were also asked to indicate whether they
had a prescription or not. The answer options for amount, times
and reasons of usage were based on questions that have previ-
ously been developed for the questionnaire “Family and Health
2003/2004” of the project “Family and Health” of the Radboud
University Nijmegen (Heatherton et al., 1991; Engels et al., 1999;
Engels and Knibbe, 2000; Harakeh et al., 2005). Specific categories
and answer options for amount and times of usage were different
for certain substance categories. Therefore, they will be dis-
cussed in the following sections regarding the specific substances.
Answer options for amounts and times of usage of substances
which were not present in the “Family and Health 2003/2004”
were created based on questions asked on a similar substance in
the questionnaire.
The “Family and Health 2003/2004” questionnaire discusses
four general reasons for substance usage: coping with stress,
conformity to peers, enhancement (feeling good) and social
substance use, related to the four-factor model of alcohol use
(Cooper, 1994). We added four answer options in the question
about reasons for usage for each substance: (1) “to enhance study
performance” as this was our main target of interest, (2) “medi-
cal reasons” and (3) “to lose weight” as it applied to some of the
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Box 1 | Description of the term “smart pills” (translated from Dutch).
Some students use drugs which are only available with a prescription, without having a prescription themselves. Some other students do
have a prescription, but they use a higher dose than prescribed. When they use those drugs to improve their study results, these drugs
are called smart pills. The statements below are all about smart pills. Please fill in to what extent you agree with these statements.
Table 1 | The number of respondents using specific routes of
obtainment for prescription drugs with the purpose of cognitive
enhancement from the group of respondents who indicated to “less
than often” have a prescription for the drug themselves.
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Methylphenidate (N = 21) 17 8 5 2 0 0
Beta blocker (N = 7) 2 2 2 0 0 2
substances different than alcohol on which the four-factor model
was based, and (4) “other” to provide respondents with an answer
option in case their answer was not in the list.
From these questions specific measures per substance (cate-
gory) were derived. The amount of nonmedical users was cal-
culated by including all users of the substance (category) who
reported to at least sometimes (on a four-point scale of seldom;
sometimes; regularly; often) use the substance for any other than
“medical reasons” (exception: general prescription drug use, for
which this measure could only be calculated for users who do
not have a prescription themselves). The amount of users using
a substance (category) without a prescription was calculated by
including all users of the substance (category) minus the users
who reported to use the substance without “regularly” or “often”
(similar four-point scale of seldom; sometimes; regularly; often)
to have a prescription. The amount of users using the substance
(category) with the purpose of cognitive enhancement was calcu-
lated by including all users of the substance who reported to use
the substance at least sometimes “to enhance study performance”
(similar four-point scale).
Opinions: prescription drug use for cognitive enhancement
Further, we were interested in the attitude of our respondents
toward the use of prescription drugs for the purpose of cognitive
enhancement. Respondents were presented with 17 statements
and consequently asked to provide a response on a five-point
Likert scale, indicating their (dis) agreement with the statement at
hand (see Table 2 for the list of statements). Before reading these
statements we presented a short description of the term “smart
pills” to the respondents (see Box 1 for a translated version of the
Dutch text).
DATA ANALYSIS
The first hypothesis, regarding polydrug use, has two compo-
nents. Chi-square analyses were conducted to examine whether
users of prescription drugs are more or less likely to use other
substances than non-users. Secondly, Chi-square analyses were
conducted to examine the association between the use of pre-
scription drugs, illicit drugs, and lifestyle drugs for the purpose
of cognitive enhancement. The second hypothesis, regarding the
relationship between substance use for cognitive enhancement
and stress, was examined with One-Way ANOVA’s for the differ-
ences in perceived study stress scores between users and non-users
according to our different operationalizations. P-values <0.05
(two-tailed) were considered statistically significant. The analyses
were conducted with IBM SPSS Statistics version 22.0.
RESULTS
PRESCRIPTION DRUG USE
Use of specific prescription drugs
None of the respondents reported to use rivastigmine or
modafinil. In our sample, 52 students indicated to have used
methylphenidate, while 36 students indicated to have used beta
blockers. Nonmedical use (at least “sometimes” use for any other
reason than medical) of methylphenidate was self-reported by
80.8% of methylphenidate users (2.8% of the total sample of
respondents) and 61.1% of beta blockers users (1.5% of the total
sample of respondents). Total nonmedical use of specific prescrip-
tion drugs in the sample is 4.0% (due to four users using both beta
blockers and methylphenidate at least sometimes for nonmedical
purposes). Excluding the respondents who indicated to “regu-
larly” or “often have a prescription” results in 2.4% of respondents
reporting to use prescription drugs at least sometimes for a
nonmedical purpose without having prescription.
From the methylphenidate users 73.1% (2.5% of the total
sample of respondents) reported to use methylphenidate at least
sometimes for the specific purposes of improving ones study
results (cognitive enhancement). From the beta blocker users
38.9% (0.9% of the total sample of respondents) reported to
use beta blockers at least sometimes for the specific purpose of
improving ones study results. Total specific prescription drug
use with the intention of cognitive enhancement in the sample
is 3.2%.
Furthermore, to examine the prevalence of the use of prescrip-
tion drugs for the purpose of cognitive enhancement without
having a prescription, we excluded respondents who indicated
to use prescription drugs regularly or often with a prescription.
A group of 40.4% of the methylphenidate users reported to use
methylphenidate less than often with a prescription, and at least
sometimes for the purpose of cognitive enhancement (1.4% of the
total sample of respondents). For beta blockers this prevalence
was 19.4% (0.5% of the total sample of respondents). Total use
of specific prescription drugs with (at least sometimes) the inten-
tion of cognitive enhancement without (regularly or often) having
a prescription is 1.7%. Table 1 shows via which other methods
these respondents obtained their prescription drug. Most users
without a prescription acquire the drugs via people they know.
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Use of a general group of prescription drugs
Sixty respondents (4.0% of the total sample of respondents)
admitted to use a prescription drug without having a prescription
for the drug. Forty-six respondents (3.1% of the total sample of
respondents) reported nonmedical use without a prescription (at
least “sometimes” use for any other reason than medical). From
the 60 respondents, 40% used these prescription drugs at least
sometimes to improve their study results (2.7% of the total sample
of respondents).
Opinions about prescriptions drug use for cognitive enhancement
The percentage of respondents that (dis)agreed with 17
statements about the use of “smart pills” are presented in Table 2.
Most respondents disagree with statements regarding the respon-
dent being aware of the use of smart pills. There is less agreement
about statements regarding the risks related to the use of smart
pills, the fairness of the use of smart pills, and the regulation of
the use of smart pills.
ILLICIT DRUG USE
Soft drugs, hard drugs and stimulants are considered illicit drugs.
Table 3 displays the prevalence of the use of the three categories
of illicit drugs, the use of illicit drugs for nonmedical reasons (at
least “sometimes” use for any other reason than medical) and the
use of illicit drugs with the specific purpose of cognitive enhance-
ment. Total use of illicit drugs is 20.5%. The use of illicit drugs
for nonmedical reasons is 20.4% and with the specific purpose of
cognitive enhancement (CE) 1.3%.
LIFESTYLE DRUG USE
Alcohol, nicotine, caffeine, over the counter pharmacy products,
and (legal) smart shop products are considered lifestyle drugs.
Table 4 displays the prevalence of the use of the categories of
lifestyle drugs, the use of lifestyle drugs for nonmedical reasons
(at least “sometimes” use for any other reason than medical)
and the use of lifestyle drugs with the specific purpose of cog-
nitive enhancement. Total use of lifestyle drugs is 92.8%. The use
of lifestyle drugs for nonmedical reasons is 90.5% and with the
specific purpose of cognitive enhancement 45.6%.
Table 5 provides an overview of the prevalence of the use of
certain drugs according to the above described definitions.
POLYDRUG USE
Users of specific prescription drugs with/without a prescription
reported more often the use of soft drugs, stimulants, nicotine
and over the counter pharmacy products. Users of prescription
drugs without a prescription were more likely than non-users to
report use of soft drugs, nicotine, caffeine and over the counter
pharmacy drugs. Table 6 provides the test statistics for these tests.
For most substances the data confirm the hypothesis that users of
prescription drugs for the purpose of cognitive enhancement are
more likely to use other substances than non-users of prescription
drugs for the purpose of cognitive enhancement.
Furthermore, Chi square tests of the association between
prescription drugs, illicit drugs, and lifestyle drugs for the
Table 3 | Prevalence of the use of soft drugs, hard drugs and
stimulants, calculated from the total sample.
Soft drugs (%) Hard drugs (%) Stimulants (%)
Use 19.1 1.9 4.9
Nonmedical use 19.0 1.9 4.8
Use for CE 0.7 0.1 0.6
Table 2 | Percentages of agreement toward statements about smart pills (N = 1503).
Options S
tr
o
n
g
ly
d
is
ag
re
e
D
is
ag
re
e
N
eu
tr
al
A
g
re
e
S
tr
o
n
g
ly
A
g
re
e
1. I am aware of students using “smart pills” regularly. 85.5 4.6 2.9 5.1 1.9
2. I am aware of students using “smart pills” during finals week. 83.3 4.8 2.5 6.9 2.5
3. I have spoken about “smart pills” with other students. 78.2 5.1 3.0 9.0 4.7
4. I have been offered stimulant drugs by another student. 92.6 1.7 1.3 2.8 1.6
5. I know students that I can get “smart pills” from. 84.1 3.2 2.8 5.9 4.1
6. “Smart pills” are easily accessible on this campus. 70.1 4.9 22.2 1.8 1.0
7. “Smart pills” should be freely accessible. 73.6 11.0 11.9 2.6 0.9
8. I think that it is harmless to use “smart pills.” 57.6 16.8 19.9 4.0 1.7
9. I think students consider the risks of using “smart pills” before taking them. 36.5 25.1 33.9 3.9 0.5
10. I know enough about “smart pills” to safely use them. 67.7 13.0 11.4 4.7 3.3
11. Students should be informed about the risks and possibilities of “smart pills.” 12.3 8.0 20.4 35.0 24.3
12. I think that “smart pills” provide an unfair advantage for students compared to those
that don’t take the drugs.
32.5 19.4 27.1 15.0 5.9
13. I think that the university board on the campus are aware of the use of “smart pills,” 16.2 14.0 64.7 3.8 1.3
14. I am aware of a policy on campus that bans the use of “smart pills.” 67.4 15.9 13.2 2.1 1.4
15. The use of “smart pills” should be prohibited on this campus. 10.6 11.2 38.9 21.0 18.3
16. A policy surrounding “smart pills” would allow a fair academic standard for students. 23.8 15.4 36.3 14.9 9.6
17. I think that it is illegal to take “smart pills.” 11.2 10.6 51.8 15.1 11.2
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Table 4 | Prevalence of the use of alcohol, nicotine, caffeine, over the counter pharmacy products and (legal) smart shop products, calculated
from the total sample.
Alcohol (%) Nicotine (%) Caffeine (%) Pharmacy (%) Smart shop (%)
Use 84.3 20.3 69.1 59.6 3.7
Nonmedical use 83.2 19.8 66.2 36.8 3.2
Use for CE 1.8 3.0 41.7 9.0 0.5
Table 5 | An overview of the prevalence of the use of drugs for CE.
Nonmedical use of specific prescription drugs with/without
prescription
4.0%
Nonmedical use of specific prescription drugs without a
prescription
2.4%
Use of specific prescription drugs with/without prescription
with the intention of CE
3.2%
Use of specific prescription drugs without a prescription
with the intention of CE
1.7%
Nonmedical use of general group of prescription drugs
without a prescription
3.1%
Use of general group of prescription drugs without a
prescription with the intention of CE
1.6%
Nonmedical use of illicit drug 20.4%
Use of illicit drugs with the intention of CE 1.3%
Nonmedical use of lifestyle drugs 90.5%
Use of lifestyle drugs with the intention of CE 45.6%
Table 6 | Results of the Chi square comparisons of substance use
between users and nonusers of prescription drugs, with/without and
only without a prescription.
With and without a
prescription (N = 48)
Without a
prescription
(N = 25)
χ2 Odds χ2 Odds
ratio ratio
Alcohol 2.03 2.36
Nicotine 30.98** 4.56 35.77** 8.78
Caffeine 3.41 4.24* 3.32
Pharmacy 7.87** 2.64 6.28* 3.62
Soft drugs 13.47** 2.90 22.41** 5.62
Smart shop products X X
Stimulant drugs 20.71** 5.02 X
Hard drugs X X
Significance levels are indicated with *P < 0.05 and **P < 0.01. X is used to
indicate that a statistical test was not performed as small cell sizes precluded
significance testing.
purpose of cognitive enhancement demonstrate that users of
lifestyle drugs for the purpose of cognitive enhancement are more
likely to use prescription drugs and illicit drugs for the purpose of
cognitive enhancement. This partly confirms the hypothesis that
there is an association between the use of prescription, illicit, and
lifestyle drugs for cognitive enhancement. Table 7 provides the
test statistics for these tests. Similar tests for the relation between
the use of illicit drugs for the purpose of cognitive enhancement
and prescription drugs for the purpose of cognitive enhance-
ment could not be performed because small cell sizes precluded
significance testing.
COGNITIVE ENHANCEMENT AND STRESS
Users of specific prescription drugs with/without a prescription
for the purpose of cognitive enhancement and users of lifestyle
drugs for the purpose of cognitive enhancement report more
study related stress than their respective non-user groups. This
means that our hypothesis that students who use substances for
the purpose of cognitive enhancement will report more stress
than students who do not use substances for the purpose of cog-
nitive enhancement is only confirmed for certain definitions of
cognitive enhancement drug use. Table 8 provides the according
test statistics.
DISCUSSION
The present study demonstrates the prevalence of the nonmedical
use and the use with the specific purpose of cognitive enhance-
ment of prescription drugs, illicit drugs, and lifestyle drugs
among university students in the Netherlands. General use and
nonmedical use is larger for lifestyle drugs than illicit drugs, and
larger for illicit drugs than prescription drugs. Even though preva-
lence numbers differ for general and nonmedical use, the use
of prescription drugs and illicit drugs with the purpose of cog-
nitive enhancement is rather similar and low in occurrence in
the current sample. However, almost half of the respondents use
lifestyle drugs with the intention to cognitively enhance them-
selves. Users of prescription drugs for the purpose of cognitive
enhancement are more likely to use other substances than non-
users. There is a relation between the use of prescription drugs
and the use of illicit drugs, but not with the use of lifestyle drugs
when it comes to using these substances to cognitively enhance
oneself. The hypothesis, that respondents who use substances for
cognitive enhancement experience more stress than non-users, is
confirmed for the group of users of specific prescription drugs
that include both users with and without a prescription and for
users of lifestyle drugs.
The use of substances for cognitive enhancement has not pre-
viously been examined in the university student population in
the Netherlands. However, the prevalence of the use of prescrip-
tion drugs without a prescription for the purpose of cognitive
enhancement, is in line with a study within a younger Dutch
population (14–17 year) in which 1.7% reported to use prescrip-
tion drugs—which were not prescribed to themselves or in a
different way than prescribed to them—with the intention the
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Table 7 | Results of the Chi square association between the use of prescription drugs (specific prescription drugs with/without a prescription;
specific prescription drugs without a prescription; general prescription drugs without a prescription), illicit and lifestyle drugs for cognitive
enhancement.
Specific with/without Specific without General without Illicit
χ2 OR χ2 OR χ2 OR χ2 OR
Lifestyle 22.56** 4.75 12.15** 4.89 8.51** 3.65 9.68** 4.87
Significance levels are indicated with *P < 0.05 and **P < 0.01. The odds ratio (OR) is calculated as a measure of the effect size.
Table 8 | Results of One-Way ANOVAs for the relation between the
use of prescription drugs (specific prescription drugs with/without a
prescription; specific prescription drugs without a prescription;
general prescription drugs without a prescription), illicit and lifestyle
drugs for cognitive enhancement and study related stress.
UsersM (sd) NonusersM (sd) F (df 1,1501) r
Specific w/wo 39.29 (7.74) 36.67 (6.81) 35.75* 0.067
Specific wo 38.68 (8.61) 36.72 (6.82) 2.02
General wo 38.25 (8.56) 36.73 (6.82) 1.17
Illicit 38.00 (6.61) 36.73 (6.86) 0.67
Lifestyle 37.89 (6.99) 35.79 (6.59) 35.75** 0.153
Significance levels are indicated with *P < 0.05 and **P < 0.01.
enhance performance (Ganpat et al., 2009). Compared to the
nonmedical use of prescription drugs in Wales, our result of non-
medical use is far lower (Holloway and Bennett, 2012). The same
trend is observed for the use of substances for the specific pur-
pose of cognitive enhancement. The use of specific prescription
drugs and general prescription drugs with this intention (1.7
and 1.6%) is lower than most lifetime prevalence numbers in
Europe (ranging from 4.6 to 16%) (Castaldi et al., 2012; Maier
et al., 2013; Sattler and Wiegel, 2013; Ott and Biller-Andorno,
2014; Pustovrh and Mali, 2014; Wolff et al., 2014). It might be
suggested that our numbers are lower due to their timeframe
being based on “during respondent’s university studies” instead of
lifetime prevalence. However, Eickenhorst et al. (2012) also exam-
ined use “during studies” and found a prevalence of 7%, similar
to other lifetime reports. Furthermore, the only two studies with
a low prevalence more similar to our prevalence are conducted
in Germany by Franke et al. (2011a) with a lifetime prevalence
of 0.8% and by Mache et al. (2012) with a lifetime prevalence
up to 2%.
The use of illicit drugs to enhance cognitive performance in
our sample (1.3%) is a little lower than previous prevalence num-
bers of 2.9% (Franke et al., 2011a) and 3.5% in Germany (Wolff
et al., 2014; however, a smaller difference is found when com-
paring to their finding of the point prevalence of 1.7%). When
we combine our prevalence of the use of illicit drugs and alcohol
for cognitive enhancement and compare it with the category of
drugs of abuse (7.8%) by Maier et al. (2013), the resulting preva-
lence of our study is clearly lower. The use of lifestyle drugs to
enhance cognitive performance (45.6%) is lower than found by
Wolff et al. (2014; 83.2%), but more in line with the prevalence of
the use of coffee for this purpose by 53% respondents of Franke
et al. (2011a) and what the authors report as soft enhancers (e.g.,
coffee) by about half of the respondents of Maier et al. (2013).
Again, when looking at the point prevalence instead of lifetime
prevalence of the use of lifestyle drugs for cognitive enhance-
ment (52.3%) by Wolff et al. (2014), the difference is smaller. In
general our prevalence numbers of prescription drugs and illicit
drugs appear to be low compared to research in other European
countries, whilst our results for lifestyle drugs are more in line.
One potential reason that explains the low prevalence of the
use of substances for cognitive enhancement among university
students in the Netherlands can be found by taking a closer look at
responses to statements regarding the awareness about the use of
prescription drugs for cognitive enhancement purposes. Whereas
in a Swiss sample 93.7% of the respondents and in a German sam-
ple almost 60% knew that substances could and are being used for
the purpose of cognitive enhancement, only 13.7% of our current
sample has ever spoken about the use of prescription drugs for
cognitive enhancement (Franke et al., 2011a; Maier et al., 2013).
Lesser awareness of the possibility to use substances for the pur-
pose of cognitive enhancement among peers can have an impact
on the prevalence, in particular for prescription drugs which,
when not obtained by a prescription, are often obtained via peers.
This is in line with previous research (McCabe and Boyd, 2005;
Maier et al., 2013; Ott and Biller-Andorno, 2014).
Although awareness of the use of cognitive enhancement drugs
by others is rather low (10%), it is still considerably higher than
the actual prevalence of the use of prescription drugs for cog-
nitive enhancement (1.6–3.2%). It remains unclear whether this
difference is based on the fact that respondents know the same
users, whether students overestimate the use of prescription drugs
for cognitive enhancement by other students, whether there is
a bias in sampling toward more non-users, or whether they did
not report their own use truthfully. Recent research suggests
that prevalence rates vary depending on the type of questions.
Previous research by Franke et al. (2011a) showed a prevalence
in Germany of below 1% while a more recent study, using an
altered version of the Randomized Response Technique estimated
a prevalence of 20% prescription drugs use for cognitive enhance-
ment in the German student population (Dietz et al., 2013). Dietz
et al. (2013) relates this difference to the stigmatized nature of
the topic of enhancement drug use, which would indicate that
our results demonstrate an underestimated prevalence rate due
to non-truthful answers. However, other researchers emphasize
the overestimation of the use of cognitive enhancement drugs by
peers, which would suggest that the number of 9%, of students
who know other students to be users, is unreliable, while our
actual prevalence rate is more reliable (Lucke et al., 2011).
Frontiers in Systems Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 10 | 8
Schelle et al. Cognitive enhancement substance use
In spite of the low prevalence numbers, the majority of the
students believe they ought to be receiving adequate information
about the risks and opportunities of using prescription drugs for
cognitive enhancement. This is in line with findings from pre-
vious studies on the opinions about pharmacological cognitive
enhancement in which people argued that it was important to be
able to make autonomous decisions about the use of such sub-
stances (Schelle et al., 2014). However, deciding whether or not to
give students or the general population more information about
the use of substances for cognitive enhancement is a difficult task.
Sandberg (2013) argues that on the one hand the lack of informa-
tion can create irrational demand and employer coercion when
hype will dominate, but at the same time there is not enough
information yet—especially on the long term effects—to create
a proper risk/benefit analysis.
Modafinil and rivastigmine were not reported as being used
by the students in our sample, while being proposed as two of
four specific prescription drugs that could be used for cognitive
enhancement. One explanation for this discrepancy could be that
these two drugs are not as often prescribed in the Netherlands
to students compared to methylphenidate and beta blockers. For
example, while modafinil is only 10,500 times provided by the
public pharmacies in the Netherlands in 2009, the amount of
times methylphenidate was provided was already rising to a mil-
lion prescriptions per year, which it passed in 2011 (Stichting
Farmaceutische Kengetallen, 2010, 2012). In contrast, rivastig-
mine is often prescribed to older people, which may lead to its
accessibility being scarce in the student population, especially
when compared to the amount of methylphenidate prescriptions
in the population. This explanation based on the amount of pre-
scriptions in the corresponding age population is supported by
the fact that most prescription drugs which are not obtained
by a prescription are obtained via peers, either freely or paid.
This corroborates previous studies in other countries (McCabe
and Boyd, 2005). It would be interesting to further examine
whether different populations in the Netherlands do use prescrip-
tion drugs like rivastigmine and modafinil for the purpose of
cognitive enhancement, especially focusing on those populations
for whom the specific effect of the substance is more desirable, or
the substance is more accessible. Examples of specific target pop-
ulations are academics, pilots and surgeons (see e.g., Franke et al.,
2013).
As hypothesized, users of prescription drugs for cognitive
enhancement reported more often the use of other substances
such as soft drugs, nicotine and stimulants than non-users. This
polydrug use is consistent with previous studies (Barret et al.,
2005; McCabe et al., 2005; Teter et al., 2006; Eickenhorst et al.,
2012; Mazanov et al., 2013). Polydrug use is also found in other
domains, such as doping in sport (Dunn et al., 2009; Backhouse
et al., 2013). Based on their co-occurrence Backhouse et al. (2013)
suggest that athletes who engage in legal performance enhance-
ment are an “at-risk” group for transition toward doping, the
gateway hypothesis. Our findings display that users of lifestyle
drugs for the purpose of cognitive enhancement are more likely
to use illicit drugs and prescription drugs for the purpose of
cognitive enhancement and thus support previous findings in
suggesting that this hypothesis not only plays a role in physical
performance enhancement but also for cognitive performance
enhancement.
Furthermore, in accordance with previous studies there is
an association between the use of prescription drugs and illicit
drugs for cognitive enhancement purposes. In contrast to pre-
vious findings, no such relation was found between the use of
prescription drugs and lifestyle drugs for cognitive enhancement
purposes (Maier et al., 2013; Wolff and Brand, 2013; Ott and
Biller-Andorno, 2014). An explanation of this discrepancy can be
found in the way that the category of lifestyle drugs is approached
and measured. Ott and Biller-Andorno (2014) found that use of
cigarettes could explain variance in their logistic regressionmodel
about cognitive enhancement drug use, while coffee did not.
Another explanation might be found in the low awareness about
the use of prescription drugs for cognitive enhancement in the
current sample. There might be a higher discrepancy between the
awareness of the use of prescription drugs for cognitive enhance-
ment and the use of lifestyle drugs for cognitive enhancement
than in other countries, resulting in less association between the
two types of cognitive enhancement drug use.
Finally, it was proposed that students who use substances for
the purpose of cognitive enhancement report more stress than
non-users. This hypothesis is confirmed for the group of users
of specific prescription drugs that include users with and with-
out a prescription, and for the group of users of lifestyle drugs
for cognitive enhancement. Lifestyle drugs are most commonly
used for cognitive enhancement in our sample, by almost half of
all respondents. Our findings suggest that stress might be a pre-
dicting factor for using lifestyle drugs for cognitive enhancement.
A similar longitudinal study as Sattler and Wiegel (2013) con-
ducted on the relation between cognitive test anxiety and the use
of prescription drugs for cognitive enhancement would inform
whether the use of lifestyle drug use is a coping mechanism for
(study related) stress or a potential cause of stress. The finding
that there is no relation between the use of illicit drugs for cog-
nitive enhancement and stress is supported by previous findings
of Wolff et al. (2014) and Wolff and Brand (2013) but not Maier
et al. (2013). More research is needed to explore these contrasting
findings. Furthermore, future research can also give more insight
in why students in the Netherlands who indicate to use a gen-
eral group of prescription drugs for cognitive enhancement, or
specific prescription drugs without having a prescription, do not
confirm the previous associations between prescription drugs use
for cognitive enhancement and stress (Maier et al., 2013; Sattler
and Wiegel, 2013; Wolff et al., 2014).
In this study, a differentiation between different operational-
izations of cognitive enhancement substance use is presented. By
displaying results based on different operationalizations we aim to
create the possibility to compare our results with as many studies
as possible and inform the debate about differences in the result
due to different research methods. As several of the prevalence
numbers of the use of substances for cognitive enhancement in
our sample are rather low, large differences between the oper-
ationalizations have not arisen. However, our findings suggest
that there is less influence of asking about specific prescription
drugs vs. a general kind of prescription drugs than there is influ-
ence of including or not including users with a prescription for a
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prescription drug. Furthermore, our findings demonstrate a large
difference between asking nonmedical use of any substance or
asking about use for the specific purpose of cognitive enhance-
ment. This supports the importance of a means-to-end relation
as proposed by Wolff and Brand (2013) and Wolff et al. (2014).
In addition to the different operationalizations that were pro-
posed in an attempt to tackle most differences between studies
on the prevalence of the use of substances for cognitive enhance-
ment, a further topic of interest is found. Recently, more andmore
researchers start including not only the use of prescription drugs,
but also the use of illicit and lifestyle drugs in the debate about
cognitive enhancement. It was hard to define which substances
belong to which overarching categories, as several frameworks
can be chosen to underlie these categories (e.g., legal; norma-
tive acceptance; accessibility). Therefore, different categories are
used, such as lifestyle drugs vs. soft enhancers (Maier et al., 2013;
Wolff et al., 2014) and illicit drugs vs. drugs of abuse (Franke
et al., 2011a; Maier et al., 2013; Wolff et al., 2014). When one
wants to relate the use of a certain category of substances to for
example stress, it is clear that these relations depend on the type
of substances included in a certain category. We aimed to create
transparency about this topic by providing the prevalence number
for each specific substance within each category separately.
LIMITATIONS
A limitation to this study is the sample which, due to conve-
nience sampling, constituted only an approximate representation
of the student population in the Netherlands. Women, for exam-
ple, were oversampled. In addition, the sample was not equally
distributed for different universities, as well as not distributed in
line with the absolute difference in amount of students of the
14 Dutch government supported universities. However, the per-
centages of recreational substance use obtained in our sample
are lower, but within normal limits, than numbers specified in
the National Drug Monitor in the Netherlands (Van Laar et al.,
2012). This indicates that, regarding our main topic of drug use,
our sample is representative for the population. Therefore, no
weighting strategies are applied.
Furthermore, it is clear that although the use of substances
for cognitive enhancement is mostly examined in student pop-
ulations, it is probably not possible to generalize this to other
populations. This is supported by the prevalence rate of prescrip-
tion drug use for cognitive enhancement of 11% among Dutch
psychiatrists, which is rather high compared to the prevalence in
the current sample (Timmer and Glas, 2012). Even similar aged
non-student populations may demonstrate a different pattern of
use (Herman-Stahl et al., 2007). Future studies will need to give
more insight in the use of substances for cognitive enhancement
in other target groups such as in specific occupations, or specific
age groups, both within the Netherlands as abroad.
A final limitation regards the study methods. The research is
conducted by an online large-scale self-report questionnaire with
many questions which might have given rise to a decrease of the
feeling of anonymity, a burden in the time that was needed to
complete the questionnaire, or for example a lack of memory
about certain situations and feelings during the use of certain
substances. It is possible that the use of certain substances is
stigmatized (Dietz et al., 2013), which may lead to a different
reported prevalence rate compared to the actual prevalence rates.
CONCLUSION
To sum up, the present study indicates that the use of prescrip-
tion drugs and illicit drugs to increase cognitive performance
among students in Dutch universities is rather low compared
to other European countries, while the use of lifestyle drugs for
cognitive enhancement fits the European context better. We have
found further evidence of polydrug use in relation to cognitive
enhancement, while previous findings of the relation between
cognitive enhancement drug use and stress have not been con-
firmed consistently. We have decided to report the findings of
several operationalizations of cognitive enhancement drug use to
enable comparison with a wider variety of previous and upcom-
ing research. We urge future researchers to take the discussion
about these different operationalizations and the effects that
they have on the prevalence numbers into account in designing
and reporting future experiments on the use of substances for
cognitive enhancement.
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